Wall Street expects a year-over-year increase in earnings on higher revenues when Range Resources (RRC) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 22. ...

Wall Street expects a year-over-year decline in earnings on higher revenues when NVR (NVR) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lo ...

Company Performance - WaFd reported quarterly earnings of $0.65 per share, exceeding the Zacks Consensus Estimate of $0.60 per share, but down from $0.73 per share a year ago, representing an earnings surprise of 8.33% [1] - The company posted revenues of $179.79 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.38%, compared to year-ago revenues of $171.99 million [2] - Over the last four quarters, WaFd has surpassed consensus EPS estimates three times and topped consensus revenue estimates only once [2] Stock Performance - WaFd shares have declined approximately 24.1% since the beginning of the year, while the S&P 500 has decreased by 10.4% [3] - The current consensus EPS estimate for the upcoming quarter is $0.64 on revenues of $194.36 million, and for the current fiscal year, it is $2.48 on revenues of $755.03 million [7] Industry Outlook - The Zacks Industry Rank for Banks - West is currently in the bottom 46% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Solventum (SOLV) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.This health care company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 13.24%.For the last reported quarter, S ...

Reinsurance Group of America, Incorporated (RGA) shares are trading at a discount to the Zacks Life Insurance industry. Its forward price-to-book value of 1.2X is lower than the industry average of 1.83X, the Finance sector’s 4.05X and the Zacks S&P 500 Composite’s 7.89X. The life insurer has a Value Score of A.The insurer has a market capitalization of $13.09 billion. The average volume of shares traded in the last three months was 0.5 million. Shares of Sun Life Financial Inc. (SLF) and Primerica, Inc. (P ...

Group 1: Earnings Performance - BioXcel Therapeutics reported a quarterly loss of $3.57 per share, which was better than the Zacks Consensus Estimate of a loss of $4.36, representing an earnings surprise of 18.12% [1] - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The revenue for the quarter ended December 2024 was $0.37 million, exceeding the Zacks Consensus Estimate by 144%, although it was slightly down from $0.38 million a year ago [2] Group 2: Stock Performance and Outlook - BioXcel Therapeutics shares have declined approximately 63.6% since the beginning of the year, contrasting with the S&P 500's decline of 2.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is -$2.72 on revenues of $0.3 million, and for the current fiscal year, it is -$16.32 on revenues of $3.51 million [7] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which BioXcel Therapeutics belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

Core Insights - Palmer Square Capital BDC Inc. (PSBD) reported revenue of $34.87 million for the quarter ended December 2024, reflecting a 17% increase year-over-year [1] - The earnings per share (EPS) for the quarter was $0.46, down from $0.58 in the same quarter last year [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $34.89 million, resulting in a revenue surprise of -0.05% [1] - The company experienced an EPS surprise of -4.17%, with the consensus EPS estimate being $0.48 [1] Performance Metrics - Investment income from non-controlled, non-affiliated investments showed varied results: - Other income was reported at $0.28 million, below the average estimate of $0.40 million [4] - Dividend income was $0.66 million, compared to the average estimate of $0.70 million [4] - Interest income was reported at $33.25 million, slightly below the average estimate of $33.65 million [4] - Over the past month, shares of Palmer Square Capital BDC Inc. returned -1.9%, compared to a -2.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

分组1 - Hilton Grand Vacations (HGV) reported quarterly earnings of $0.49 per share, missing the Zacks Consensus Estimate of $0.76 per share, and down from $1.01 per share a year ago, representing an earnings surprise of -35.53% [1] - The company posted revenues of $1.28 billion for the quarter ended December 2024, missing the Zacks Consensus Estimate by 0.89%, compared to year-ago revenues of $1.02 billion [2] - Over the last four quarters, Hilton Grand Vacations has surpassed consensus EPS estimates only once and topped consensus revenue estimates just once [2] 分组2 - The stock has added about 4% since the beginning of the year, outperforming the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the coming quarter is $0.74 on $1.26 billion in revenues, and for the current fiscal year, it is $3.60 on $5.34 billion in revenues [7] - The Zacks Industry Rank indicates that the Hotels and Motels sector is currently in the bottom 32% of over 250 Zacks industries, which may impact stock performance [8]